Here -- without other color commentary -- is that for the first quarter:
. . .Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs. . . .
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care. . . .
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease. . . .
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality. . . .
Pharmaceutical intellectual property issues. . . .
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping. . . .
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act. . . .
This last bit is lobbying on preventing compounders from offering cheaper versions of the GLP-1 weight loss packages.
Onward, smiling -- and, we still don't know what the longer term side effect profiles will be -- for this class of blockbuster drugs. It concerns me that it is becoming seen by the low-information public, as a "cosmetic" drug. But one you'll likely need to stay on, for life. Yikes.
नमस्ते
No comments:
Post a Comment